Our study fills the pharmacological research gap concerning BO in the field of tumors for the first time by systematically interpreting the mechanism of BO’s treatment of breast cancer by regulating STAT3 through network pharmacology, molecular docking, molecular dynamics simulations, and experimental verification and, thus, providing a potential novel therapeutic agent for TNBC. Here, STAT3 is linked to bronchiolitis obliterans syndrome.